Article
Comparison of genotypic and phenotypic HIV type 1 tropism assay: results from the screening samples of Cenicriviroc Study 202, a randomized phase II trial in treatment-naive subjects.
AIDS research and human retroviruses - 1 Feb 2014
Kagan Ron M, Johnson Erik P, Siaw Martin F, Van Baelen Ben, Ogden Richard, Platt Jamie L, Pesano Rick L, Lefebvre Eric
Abstract excerpt
Cenicriviroc is a once-daily oral CCR5/CCR2 antagonist in development for treatment of HIV infection. CVC Study 202 (652-2-202; NCT01338883) excluded treatment-naive subjects demonstrated to harbor non-R5 (CXCR4-tropic or dual-mixed) tropic HIV-1 by either genotypic or phenotypic tropism testing. Here we compare the results of genotypic and phenotypic tropism testing in Study 202. A total of 304 subjects screened...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.